131 related articles for article (PubMed ID: 34174024)
41. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
42. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
43. Melanoma in 2017: Moving treatments earlier to move further forwards.
Davies MA; Flaherty KT
Nat Rev Clin Oncol; 2018 Feb; 15(2):75-76. PubMed ID: 29182162
[TBL] [Abstract][Full Text] [Related]
44. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.
Mistry HB; Orrell D; Eftimie R
Cancer Chemother Pharmacol; 2018 Feb; 81(2):325-332. PubMed ID: 29222604
[TBL] [Abstract][Full Text] [Related]
45. Fine needle aspiration of salivary gland lesions with multinucleated giant cells.
Daneshbod Y; Khademi B; Kadivar M; Ganjei-Azar P
Acta Cytol; 2008; 52(6):671-80. PubMed ID: 19068670
[TBL] [Abstract][Full Text] [Related]
46. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Johnson AS; Crandall H; Dahlman K; Kelley MC
J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
[TBL] [Abstract][Full Text] [Related]
47. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
48. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
[No Abstract] [Full Text] [Related]
49. Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
Guerra RL; Corrêa FM; Fernandes RRA; Zimmerman IR
Value Health Reg Issues; 2019 Dec; 20():103-109. PubMed ID: 31174179
[TBL] [Abstract][Full Text] [Related]
50. Subtyping salivary gland neoplasm of uncertain malignant potential based on cell type demonstrates differential risk of malignancy.
Hang JF; Alruwaii F; Zeng BR; Lai CR; Wu HH
Cancer Cytopathol; 2018 Nov; 126(11):924-933. PubMed ID: 30335220
[TBL] [Abstract][Full Text] [Related]
51. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
53. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
54. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
55. Ancillary testing strategies in salivary gland aspiration cytology: A practical pattern-based approach.
Griffith CC; Siddiqui MT; Schmitt AC
Diagn Cytopathol; 2017 Sep; 45(9):808-819. PubMed ID: 28411379
[TBL] [Abstract][Full Text] [Related]
56. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
[No Abstract] [Full Text] [Related]
57. Fine needle aspiration biopsy of metastatic malignant melanoma with "rhabdoid" features. Frequency, cytologic features, pitfalls and ancillary studies.
Slagel DD; Raab SS; Silverman JF
Acta Cytol; 1997; 41(5):1426-30. PubMed ID: 9334131
[TBL] [Abstract][Full Text] [Related]
58. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
[TBL] [Abstract][Full Text] [Related]
59. A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy.
Mormando M; Puliani G; Barnabei A; Lauretta R; Bianchini M; Chiefari A; Russillo M; Cognetti F; Romano L; Appetecchia M
Front Endocrinol (Lausanne); 2020; 11():471. PubMed ID: 32793120
[No Abstract] [Full Text] [Related]
60. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]